Furthermore, the Reach for Health study demonstrated that improved glycaemic control achieved via metformin therapy and weight loss had a positive impact on the plasma insulin, SHBG and oestrogen concentrations in postmenopausal breast cancer survivors who were either overweight or obese [111]. This evidence concerns the gene SHBG and breast carcinoma.